Prevalence of Ocular Manifestations and Visual Outcomes in Patients With Herpes Zoster Ophthalmicus

Purpose: To investigate the prevalence of ocular manifestations and visual outcomes in patients with herpes zoster ophthalmicus (HZO). Methods: Consecutive cases diagnosed with HZO who attended 2 hospitals between July 1, 2011, and June 30, 2015, were retrospectively reviewed. Patient demographics, clinical presentations, and management were reviewed. The logistic regression model was used to estimate the odds ratio of visual loss with ocular manifestations. Results: A total of 259 patients were included. Of these, 110 (42.5%) patients were <60 years old and 149 patients (57.5%) were ≥60 years old. None of the patients had received zoster vaccination before presentation. Ocular manifestations were present in 170 (65.6%) patients with no difference between both age groups (P = 0.101). Conjunctivitis was the most common ocular manifestation, followed by anterior uveitis and keratitis. After resolution of HZO, 58.7% of patients had a visual acuity of 6/12 or worse. Epithelial keratitis and stromal keratitis were independent risk factors for visual loss after resolution of HZO (P = 0.003 and P = 0.004, respectively). The corresponding odds ratio was 6.59 [95% confidence interval (CI): 1.87–23.19] and 7.55 (95% CI: 1.88–30.30), respectively. The number of ocular manifestations was also associated with an increased risk of visual loss with an odds ratio of 1.49 (95% CI: 1.01–2.20; P = 0.043). Conclusions: A substantial proportion of patients with HZO were <60 years old in this study. The absence of zoster vaccination across the study cohort was noteworthy. Keratitis was the main reason for poor visual outcome in these patients.

[1]  E. Cohen Management and Prevention of Herpes Zoster Ocular Disease. , 2015, Cornea.

[2]  J. Chodosh,et al.  Herpes zoster ophthalmicus: declining age at presentation , 2015, British Journal of Ophthalmology.

[3]  E. Cohen,et al.  Persistent dilemmas in zoster eye disease , 2015, British Journal of Ophthalmology.

[4]  M. Khairallah,et al.  Ocular involvement and visual outcome of herpes zoster ophthalmicus: review of 45 patients from Tunisia, North Africa , 2014, Journal of Ophthalmic Inflammation and Infection.

[5]  M. Melbye,et al.  The Short- and Long-Term Risk of Stroke after Herpes Zoster - A Nationwide Population-Based Cohort Study , 2013, PloS one.

[6]  E. Cohen,et al.  Herpes Simplex and Herpes Zoster Eye Disease: Presentation and Management at a City Hospital for the Underserved in the United States , 2013, Eye & contact lens.

[7]  B. Yawn,et al.  Herpes zoster eye complications: rates and trends. , 2013, Mayo Clinic proceedings.

[8]  E. Esterberg,et al.  Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study. , 2013, Ophthalmology.

[9]  S. Weinmann,et al.  Safety of zoster vaccine in adults from a large managed‐care cohort: a Vaccine Safety Datalink study , 2012, Journal of internal medicine.

[10]  Ivan S F Chan,et al.  Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Herng‐Ching Lin,et al.  Increased risk of anterior uveitis following herpes zoster: a nationwide population-based study. , 2012, Archives of ophthalmology.

[12]  E. Cohen,et al.  Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. , 2011, Ophthalmology.

[13]  A. Thakur,et al.  Ocular manifestations in herpes zoster ophthalmicus. , 2011, Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH.

[14]  S. Nithyanandam,et al.  Factors affecting visual outcome in herpes zoster ophthalmicus: a prospective study , 2010, Clinical & experimental ophthalmology.

[15]  B. Yawn,et al.  Health care utilization and cost burden of herpes zoster in a community population. , 2009, Mayo Clinic proceedings.

[16]  S. Nithyanandam,et al.  Eruption severity and characteristics in herpes zoster ophthalmicus: correlation with visual outcome, ocular complications, and postherpetic neuralgia , 2009, International journal of dermatology.

[17]  S. Kaufman Anterior segment complications of herpes zoster ophthalmicus. , 2008, Ophthalmology.

[18]  T. Liesegang Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. , 2008, Ophthalmology.

[19]  P. Peduzzi,et al.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2005, The New England journal of medicine.

[20]  G. Oster,et al.  Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. , 2005, The journal of pain : official journal of the American Pain Society.

[21]  A. Hall,et al.  For Personal Use. Only Reproduce with Permission from the Lancet. Review Risk Factors for Herpes Zoster What Does Epidemiology Tell Us about Risk Factors for Herpes Zoster? , 2022 .

[22]  H. Völker‐Dieben,et al.  Visual prognosis in immunocompetent patients with herpes zoster ophthalmicus. , 2003, Acta ophthalmologica Scandinavica.

[23]  I. Schwab Herpes zoster sine herpete. A potential cause of iridoplegic granulomatous iridocyclitis. , 1997, Ophthalmology.

[24]  Aaron E. Miller Selective decline in cellular immune response to varicella‐zoster in the elderly , 1980, Neurology.